LiberoThera

Executive Summary

LiberoThera is a Japanese biotechnology company specializing in drug discovery targeting membrane proteins, with a focus on immunology and oncology. Founded in 2018 and based in Tokyo, the company has raised $10 million in funding and is currently in the preclinical stage. LiberoThera's core technologies include cell-free membrane protein preparation and non-canonical amino acid incorporation, enabling the generation of fully human antibodies against challenging targets such as GPCRs. Their lead program is an anti-CCR8 antibody, which holds promise for cancer immunotherapy by modulating regulatory T cell activity. The company's innovative platform addresses the historically difficult-to-drug membrane protein class, positioning it as a potential player in the antibody therapeutics space. With a lean team of 10-50 employees, LiberoThera is focused on advancing its pipeline towards clinical development, though near-term revenue is not expected.

Upcoming Catalysts (preview)

• Q4 2026Preclinical proof-of-concept data for anti-CCR8 antibody60% success
• Q2 2027Series A financing or partnership announcement50% success
• H1 2027IND filing for lead anti-CCR8 program40% success